Recent advances in the treatment of hepatitis C

Discovery Medicine

Volumn 18, Issue 99, 2014, Pages 203-208

  Dhingra, Abhinav ^a   Kapoor, Saloni ^a   Alqahtani, Saleh A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; DACLATASVIR; DASABUVIR; ELBASVIR; GRAZOPREVIR; INTERFERON; LEDIPASVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMBITASVIR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERINE PROTEINASE INHIBITOR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; TELEPREVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CARRIER PROTEIN; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; URIDINE PHOSPHATE; VIRAL PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; LIFE CYCLE STAGE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; HEPACIVIRUS; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIVIRAL AGENTS; CARRIER PROTEINS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; RIBAVIRIN; SOFOSBUVIR; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84925851796     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, Marcellin P, Balart L, Alberti A, Craxi A. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 39(2):333-342, 2004.
2. Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, Zeng W, Murray J, Birnkrant D. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 144(7):1450-1455.e1452, 2013.
3. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902):359-362, 1989.
4. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140(5):346-355, 2004.
5. Jacobson I, Dore GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Kalmeijer R, Beumont-Mauviel M. 1425 simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from quest-1, a phase III trial. J Hepatol 58:S574, 2013a.
6. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, SchiffE, Al-Assi MT, Subramanian GM, An D, Lin M, Mcnally J, Brainard D, Symonds WT, Mchutchison JG, Patel K, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368(20):1867-1877, 2013b.
7. Kim AI, Dorn A, Bouajram R, Saab S. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis. HIV Med 8(5):312-321, 2007.
8. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 381(9883):2100-2107, 2013.
9. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, Mcnally J, Brainard D, Symonds WT, et al. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. N Engl J Med 368(20):1878-1887, 2013a.
10. Lawitz E, Vierling JM, Murillo A. High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172/MK-8742 +/- RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study. Hepatology 58(Suppl 1):244A, 2013b.
11. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 156(4):271-278, 2012.
12. Manns M, Marcellin P, Fred Poordad FP, Stanislau Affonso De Araujo E, Buti M, Horsmans Y, Ewa Janczewska EJ, Villamil F, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Kalmeijer R, Beumont-Mauviel M. 1413 simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from quest-2, a phase III trial. J Hepatol 58:S568, 2013.
13. Mchutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, Mccone J, Nyberg LM, Lee WM, Ghalib RH, SchiffER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361(6):580-593, 2009.
14. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57(4):1333-1342, 2013.
15. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45(4):529-538, 2006.
16. Poordad F, Mccone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, Dinubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13):1195-1206, 2011.
17. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 43(1):66-72, 2011.
18. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 85(Pt 11):3173-3188, 2004.
19. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 8(3):280-288, 288.e281, 2010.
20. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein DB, Patel N, Alter M, Yartel A, Ward JW. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 61(Rr-4):1-32, 2012.
21. Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 13(3):313-323, 2012.
22. Sulkowski MS, Jacobson IM, Ghalib R, Rodriguez-Torres M, Younossi Z, Corregidor A, Fevery B, Callewaert K, Symonds W, Rosa GDL, Picchio G, Ouwerkerk-Mahadevan S, Lambrecht T, Lawitz E. Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with METAVIR F0-2: COSMOS study subgroup analysis. Gastroenterol Hepatol (N Y) 9(6 Suppl 3):1-18, 2014.
23. Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother 23(1):1-12, 2013.
24. Wartelle-Bladou C, Le Folgoc G, Bourliere M, Lecomte L. Hepatitis C therapy in non-genotype 1 patients: the near future. J Viral Hepat 19(8):525-536, 2012.
25. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 9(11):S1-S9, 2003.